Results 131 to 140 of about 17,845 (225)

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review

Santi Aprilianti,1,* Auliasari M Utami,1 Auliya A Suwantika,1– 3,* Neily Zakiyah,1,2,* Vanji Ikhsan Azis4 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia; 2Center of ...
Azis VI, Suwantika AA, Utami AM, Zakiyah N, Aprilianti S   +4 more
core  

Dolutegravir [PDF]

Reactions Weekly, 2020
  +4 more sources

Uridine diphosphate glucuronosyltransferase 1A1 gene polymorphisms and treatment outcomes in HIV and MTB coinfection in sub-Saharan Africa: a scoping review protocol. [PDF]

BMJ Open
Vhanda D, Musarurwa C, Chikwati RP, Muziringa M, Dandara C, Manasa J, Chirenda J, Mavenyengwa RT.   +7 more
europepmc   +1 more source

The impact of dolutegravir on the growth of HIV-exposed uninfected infants: an observational cohort study in rural Tanzania. [PDF]

EClinicalMedicine
Glanzmann S, Luoga E, Okuma J, Dotto E, Sigalla G, Franzeck FC, Nyenza E, Mnzava D, Bukuku M, Moshi L, Wilson L, Paris DH, Glass TR, Mollel GJ, Weisser M, Vanobberghen F, KIULARCO Study Group.   +16 more
europepmc   +1 more source

Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey. [PDF]

J Int AIDS Soc
Bello G, Kabaghe AN, Pals S, Kalata NL, Bighignoli B, van Oosterhout JJ, Mkungudza J, Agyemang E, Zheng DP, Panja L, Matola WB, Chitenje M, Kampira E, Zeh C, Mvula B, Alvarez B, Kagoli M, Mzumara W, Simon KR, Namakhoma I, O'Malley G, Chipeta S, Nyirenda R, da Silva J, Wadonda N, For Malawi HIV Drug Resistance Surveillance Team.   +25 more
europepmc   +1 more source

Restoring well-being: quality of life improvements following dolutegravir-based therapy after antiretroviral failure. [PDF]

Braz J Infect Dis
Lins-Kusterer L, Brites C, de Lacerda MVG, Page K, Bahia F, Luz E, Ramalho A, Wagner S, Arriaga MB, CODE research group collaborators.   +9 more
europepmc   +1 more source

One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials. [PDF]

Open Forum Infect Dis
Zheng A, Murray EJ, Brennan AT, Greener R, Kileel EM, Bor J, Venter WDF, Pisa PT, Fox MP, Maskew M.   +9 more
europepmc   +1 more source

Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis

International audienceBackground: For children with HIV on antiretroviral therapy (ART), transitioning to dolutegravir-containing regimens is recommended. The aim of this study was to assess whether introducing viral load testing to inform new nucleoside
Crichton, Siobhan, Bacha, Jason, Abrams, Elaine, Flanagan, Clare, Neilan, Anne, Brenner, Isaac Ravi, Collins, Intira Jeannie, Webb, Karen, Horsfall, Stephanie, Davies, Mary-Ann, Freedberg, Kenneth, Hyle, Emily, Desmonde, Sophie, Penazzato, Martina, Ciaranello, Andrea   +14 more
core   +1 more source

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro. [PDF]

Open Forum Infect Dis
Saladini F, Giannini A, Giammarino F, Antonova A, Ozhmegova E, Kaiser R, Dragoni F, Boccuto A, Vicenti I, Sönnerborg A, Bobkova M, Zazzi M.   +11 more
europepmc   +1 more source

Virtual screening and cellular validation of dolutegravir as a BRD9 inhibitor for attenuating pyroptosis in peritoneal mesothelial cells. [PDF]

Ren Fail
Gai J, Xing X, Gong C, Teng Y, Chen S, Yang M, Lou W.   +6 more
europepmc   +1 more source